BIA
AQST icon

Bell Investment Advisors’s Aquestive Therapeutics AQST Stock Holding History

Bell Investment Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-500
Closed -$2.79K – 1813
2025
Q3 		$2.79K Buy
+500
New +$2.16K ﹤0.01% 1198

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bell Investment Advisors's AQST Position: Q4 2025 in Review

Bell Investment Advisors sold out of Aquestive Therapeutics (AQST) in Q4 2025, closing a stake of 500 shares — an estimated $2.79K sold.

Bell Investment Advisors first reported a position in AQST in Q3 2025 and held it in 1 quarter. The position peaked at $2.79K in Q3 2025. 177 funds tracked by Wall St. Rank hold AQST as of Q4 2025.

  • Bell Investment Advisors reported no remaining Aquestive Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bell Investment Advisors sold 500 Aquestive Therapeutics shares in Q4 2025, an estimated $2.79K.
  • Bell Investment Advisors first reported a position in Aquestive Therapeutics in Q3 2025 and held it in 1 quarter.
  • Bell Investment Advisors's Aquestive Therapeutics position peaked at $2.79K in Q3 2025.
  • 177 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2025.

Based on Bell Investment Advisors's 13F filing for Q4 2025, filed 24 Feb 2026.